Ticker
ACER

Price
1.17
Stock movement down
-0.02 (-1.96%)
Company name
Acer Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
18.23M
Ent verdi
39.00M
Pris/omsetning
50.63
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-46.89%
3 års avkastning
-29.96%
5 års avkastning
-41.90%
10 års avkastning
-38.14%
Sist oppdatert: 2022-11-29

UTBYTTE

ACER betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning50.63
Pris til bok-
EV i forhold til salg108.33

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall15.60M
EPS (TTM)-0.76
FCF per aksje (TTM)-0.44

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)360.00K
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)-11.49M
Netto inntekt (TTM)-10.92M
EPS (TTM)-0.76
EPS (1 år fremover)-0.29

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-3190.72%
Fortjenestemargin (TTM)-3033.59%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter20.80M
Netto fordringer0.00
Samlede omløpsmidler23.35M
Goodwill7.65M
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler31.47M
Leverandørgjeld2.02M
Kortsiktig/nåværende langsiktig gjeld13.33M
Sum kortsiktig gjeld27.58M
Sum gjeld41.57M
Aksjonærenes egenkapital-10.10M
Netto varige driftsmidler-10.10M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-6.15M
Kapitalutgifter (TTM)78.55K
Fri kontantstrøm (TTM)-6.23M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-
Avkastning på eiendeler-34.70%
Avkastning på investert kapital108.11%
Kontantavkastning på investert kapital61.69%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning1.20
Daglig høy1.21
Daglig lav1.15
Daglig volum34K
Tidenes høyeste414221.04
1 år analytikerestimat9.67
Beta1.40
EPS (TTM)-0.76
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon28 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACERS&P500
Nåværende prisfall fra toppnotering-100.00%-17.12%
Høyeste prisfall-100.00%-56.47%
Dato for høyeste fall28 Nov 20229 Mar 2009
Gj.snittlig fall fra topp-98.81%-11.46%
Gj.snittlig tid til ny topp414 days13 days
Maks tid til ny topp4510 days1805 days
SELSKAPSOPPLYSNINGER
ACER (Acer Therapeutics Inc) company logo
Markedsverdi
18.23M
Markedsverdi kategori
Small-cap
Beskrivelse
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Ansatte
39
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Christopher Schelling
Land
USA
By
Newton
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
NEWTON, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious,...
30. november 2022
Acer Therapeutics ( NASDAQ:ACER ) Third Quarter 2022 Results Key Financial Results Net loss: US$5.01m (loss widened by...
17. november 2022
NEWTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious,...
14. november 2022
Notice of allowance of celiprolol method of treatment of vEDS patent application strengthens proprietary position in U.S. until 2038NEWTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics I...
26. oktober 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update...
18. oktober 2022
$3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients Proposed investigator sponsored trial to evaluate th...
6. oktober 2022
Acer Therapeutics Inc (NASDAQ: ACER) expanded ACER-801 (osanetant) into a new indication for the reduction of the frequency and severity of acute stress disorder and post-traumatic stress disorder (PT...
5. oktober 2022
Licensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant Osanetan...
5. oktober 2022
Notice of allowance covering these claims further strengthens ACER-001 proprietary position in US; patent expected to be issued in Q4 2022 and expire in 2038NEWTON, Mass. and GENEVA, Oct. 03, 2022 (GL...
3. oktober 2022
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
30. september 2022
Neste side